Megan Duster

Megan Duster

Auto-generated profile, based on publicly available information

Megan Duster

Division of Infectious Disease, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
ABAnna K Barker
Anna K Barker
MDMegan Duster
Megan Duster
SVSusan Valentine
Susan Valentine
THTimothy Hess
Timothy Hess
LALaurie Archbald-Pannone
Laurie Archbald-Pannone
NSNasia Safdar
Nasia Safdar
Clostridium difficile is the most common cause of hospital-acquired infections, responsible for >450000 infections annually in the USA. Probiotics provide a promising, well-tolerated adjunct therapy to standard C. difficile infection (CDI) treatment regimens, but there is a paucity of data regarding their effectiveness for the treatment of an initial CDI. We conducted a pilot randomized controlled trial of 33 participants from February 2013 to February 2015 to determine the feasibility and health outcomes of adjunct probiotic use in patients with an initial mild to moderate CDI. The intervention was a 28 day, once-daily course of a four-strain oral probiotic capsule containing Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07 and B. lactis Bl-04. The control placebo was identical in taste and appearance. Registered at clinicaltrials.gov: trial registration number = NCT01680874. Probiotic adjunct therapy was associated with a significant improvement in diarrhoea outcomes. The primary duration of diarrhoea outcome (0.0 versus 1.0 days; P = 0.039) and two exploratory outcomes, total diarrhoea days (3.5 versus 12.0 days; P = 0.005) and rate of diarrhoea (0.1 versus 0.3 days of diarrhoea/stool diary days submitted; P = 0.009), all decreased in participants with probiotic use compared with placebo. There was no significant difference in the rate of CDI recurrence or functional improvement over time between treatment groups. Probiotics are a promising adjunct therapy for treatment of an initial CDI and should be further explored in a larger randomized controlled trial.

1 March 2017 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
GDGregory P. DeMuri
Gregory P. DeMuri
ASAlana K. Sterkel
Alana K. Sterkel
PKPhillip A. Bs Kubica
Phillip A. Bs Kubica
MDMegan N. Mt Duster
Megan N. Mt Duster
KRKurt D. Reed
Kurt D. Reed
EWEllen R. Wald
Ellen R. Wald
Group A streptococcus (GAS) is responsible for 15%–30% of cases of acute pharyngitis in children. Macrolides such as azithromycin have become popular for treating GAS pharyngitis. We report macrolide resistance rates in a primary care setting in our geographic area over the past 5 years and discuss the implications of resistance in making treatment decisions. Throat swabs were collected from children with pharyngitis from May 2011 to May 2015 in a primary care setting in Madison, Wisconsin. Susceptibility testing was performed for erythromycin and clindamycin using the Kirby–Bauer disk diffusion method. GAS was identified on 143 throat cultures. Overall, 15% of GAS isolates demonstrated nonsusceptibility for both clindamycin and erythromycin. Inducible resistance (positive D-test) was detected in 17 isolates (12%). The rate of detection of nonsusceptibility in each year of the study did not change over time. Azithromycin should only be used for patients with pharyngitis and substantial manifestations of penicillin hypersensitivity and when used, susceptibility testing should always be performed.

1 September 2007 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
ABAlexandra Brower
Alexandra Brower
OOOgi Okwumabua
Ogi Okwumabua
CMChuck Massengill
Chuck Massengill
QMQuentin Muenks
Quentin Muenks
PVPeter Vanderloo
Peter Vanderloo
KKKathy Kurth
Kathy Kurth

1 May 2014 in Journal of Obstetric, Gynecologic, & Neonatal Nursing
Verified
Journal Article
Closed access
PDF file
LHLisa Hanson
Lisa Hanson
LVLeona Vande Vusse
Leona Vande Vusse
MDMegan Duster
Megan Duster
SWSimone Warrack
Simone Warrack
NSNasia Safdar
Nasia Safdar

14 March 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SEShoshannah Eggers
Shoshannah Eggers
ABAnna K. Barker
Anna K. Barker
SVSusan Valentine
Susan Valentine
THTimothy Hess
Timothy Hess
MDMegan Duster
Megan Duster
NSNasia Safdar
Nasia Safdar
Infection by Staphylococcus aureus (S. aureus) is a major cause of morbidity and mortality. Colonization by S. aureus increases the risk of infection. Little is known about decolonization strategies for S. aureus beyond antibiotics, however probiotics represent a promising alternative. A randomized controlled trial was conducted to determine the efficacy of Lactobacillus rhamnosus (L. rhamnosus) HN001 in reducing carriage of S. aureus at multiple body sites. One hundred thirteen subjects, positive for S. aureus carriage, were recruited from the William S. Middleton Memorial Medical Center, Madison, WI, USA, and randomized by initial site of colonization, either gastrointestinal (GI) or extra-GI, to 4-weeks of oral L. rhamnosus HN001 probiotic, or placebo. Nasal, oropharyngeal, and axillary/groin swabs were obtained, and serial blood and fecal samples were collected. Differences in prevalence of S. aureus carriage at the end of the 4-weeks of treatment were assessed. The probiotic and placebo groups were similar in age, gender, and health history at baseline. S. aureus colonization within the stool samples of the extra-GI group was 15% lower in the probiotic than placebo group at the endpoint of the trial. Those in the probiotic group compared to the placebo group had 73% reduced odds (OR 0.27, 95% CI 0.07–0.98) of methicillin-susceptible S. aureus presence, and 83% reduced odds (OR 0.17, 95% CI 0.04–0.73) of any S. aureus presence in the stool sample at endpoint. Use of daily oral L. rhamnosus HN001 reduced odds of carriage of S. aureus in the GI tract, however it did not eradicate S. aureus from other body sites. ClinicalTrials.gov Identifier: NCT01321606 . Registered March 21, 2011.

27 March 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
SEShoshannah Eggers
Shoshannah Eggers
KMKristen MC Malecki
Kristen MC Malecki
PPPaul Peppard
Paul Peppard
JMJulie Mares
Julie Mares
DSDaniel Shirley
Daniel Shirley
NSNasia Safdar
Nasia Safdar
Introduction: Prevention of multidrug-resistant organism (MDRO) infections, such as those caused by methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, fluoroquinolone-resistant Gram-negative bacteria and Clostridium difficile is crucial. Evidence suggests that dietary fibre increases gut microbial diversity, which may help prevent colonisation and subsequent infection by MDROs. The aim of the Winning the War on Antibiotic Resistance (WARRIOR) project is to examine associations of dietary fibre consumption with the composition of the gut microbiota and gut colonisation by MDROs. The secondary purpose of the study is to create a biorepository of multiple body site specimens for future microbiota research. Methods and analysis: The WARRIOR project collects biological specimens, including nasal, oral and skin swabs and saliva and stool samples, along with extensive data on diet and MDRO risk factors, as an ancillary study of the Survey of the Health of Wisconsin (SHOW). The SHOW is a population-based health survey collecting data on several different health determinants and outcomes, as well as objective body measurements and biological specimens. WARRIOR participants include 600 randomly selected Wisconsin residents age 18 and over. Specimens are screened for MDRO colonisation and DNA is extracted for 16S ribosomal RNA-based microbiota sequencing. Data will be analysed to assess the relationship between dietary fibre, the gut microbiota composition and gut MDRO colonisation. Ethics and dissemination: The WARRIOR project is approved by the University of Wisconsin Institutional Review Board. The main results of this study will be published in a peer-reviewed scientific journal.